Cronos Group, Inc. (CRON)
3.34
-0.02
(-0.60%)
USD |
NASDAQ |
Oct 30, 09:40
Cronos Group Enterprise Value : 498.69M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 498.69M |
| October 28, 2026 | 494.98M |
| October 27, 2026 | 506.10M |
| October 26, 2026 | 480.15M |
| October 23, 2026 | 494.98M |
| October 22, 2026 | 530.20M |
| October 21, 2026 | 509.81M |
| October 20, 2026 | 469.03M |
| October 19, 2026 | 457.91M |
| October 16, 2026 | 443.08M |
| October 15, 2026 | 439.37M |
| October 14, 2026 | 424.54M |
| October 13, 2026 | 439.37M |
| October 12, 2026 | 443.08M |
| October 09, 2026 | 450.49M |
| October 08, 2026 | 446.79M |
| October 07, 2026 | 454.20M |
| October 06, 2026 | 470.88M |
| October 05, 2026 | 457.91M |
| October 02, 2026 | 448.64M |
| October 01, 2026 | 443.08M |
| September 30, 2026 | 476.44M |
| September 29, 2026 | 506.10M |
| September 28, 2026 | 517.22M |
| September 25, 2026 | 491.27M |
| Date | Value |
|---|---|
| September 24, 2026 | 483.86M |
| September 23, 2026 | 513.52M |
| September 22, 2026 | 524.64M |
| September 21, 2026 | 487.57M |
| September 18, 2026 | 494.98M |
| September 17, 2026 | 502.40M |
| September 16, 2026 | 472.74M |
| September 15, 2026 | 439.37M |
| September 14, 2026 | 452.35M |
| September 11, 2026 | 417.13M |
| September 10, 2026 | 424.54M |
| September 09, 2026 | 422.69M |
| September 08, 2026 | 433.81M |
| September 04, 2026 | 461.62M |
| September 03, 2026 | 461.62M |
| September 02, 2026 | 454.20M |
| September 01, 2026 | 506.10M |
| August 31, 2026 | 502.40M |
| August 28, 2026 | 506.10M |
| August 27, 2026 | 509.81M |
| August 26, 2026 | 569.13M |
| August 25, 2026 | 554.30M |
| August 24, 2026 | 517.22M |
| August 21, 2026 | 480.15M |
| August 20, 2026 | 446.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lexaria Bioscience Corp. | 2.306M |
| Target Group, Inc. (Canada) | 11.78M |
| InMed Pharmaceuticals, Inc. | 6.442M |
| XORTX Therapeutics, Inc. | 0.7885M |
| NervGen Pharma Corp. | 92.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 35.66M |
| Revenue (Quarterly) | 53.01M |
| Total Expenses (Quarterly) | 20.92M |
| EPS Diluted (Quarterly) | 0.0855 |
| Gross Profit Margin (Quarterly) | 52.96% |
| Profit Margin (Quarterly) | 67.28% |
| Earnings Yield | 5.51% |
| Normalized Earnings Yield | 5.928 |